Loading...
Market
Rapport Therapeutics receives FDA approval for a new drug by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA announcements and company press releases
Story
Rapport Therapeutics Prices IPO at $17, Raises $154M with 22% Gain
Jun 7, 2024, 11:20 AM
Rapport Therapeutics Inc. (RAPP) successfully priced its initial public offering (IPO) at $17 per share, raising $136 million. The IPO involved 8 million shares and the company opened trading at $18 per share, marking a 5.9% increase from the IPO price. The shares rose nearly 6% in their market debut, valuing the company at $636.8 million. Rapport Therapeutics, backed by Johnson & Johnson's venture capital arm, is a clinical-stage biotechnology company focused on developing precision neuromedicines for central nervous system disorders. The company's stock market debut reaped $154 million, and it posted a 22% gain in its NASDAQ debut.
View original story
Similar markets
Below $10 • 33%
$10 to $20 • 34%
Above $20 • 33%
Underperform • 33%
Match • 34%
Outperform • 33%
Loss • 33%
Breakeven • 34%
Profit • 33%
Additional Phase 3 trials • 33%
FDA Approval without additional trials • 33%
FDA Rejection • 33%
